Jai Radhakrishnan, MD, MBBS, MS, FASN, discusses why IgG4-related kidney disease is often missed and what the MITIGATE subgroup data presented at ASN Kidney Week 2026 show.
|Videos|January 29, 2018
What Was the Most Notable Orphan Drug Approval in 2017?
Joy Gilbert, Vice President, Operations, US Bioservices, a part of AmerisourceBergen, discusses the importance of new orphan drug approvals for patients.
Advertisement
Gilbert: Well, it’s interesting because there are many orphan drugs that have been approved and are in the pipeline, but for a patient who has an orphan or rare disease, whichever one is treating their disease is the most notable.
Many of these patients have not had treatment options before. So, the most important one is the one that is treating you, as the patient, or your family member.
Advertisement
Related to this article
Doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd (Voceryq) targets HPV-6 and HPV-11 to reduce the surgical burden for adults with the rare airway disease.
Pharmacists can reduce COVID-19 vaccine hesitancy through honest, nonjudgmental communication and by using every patient touchpoint as an opportunity to offer vaccination.
From AKI dosing to CKM therapeutic inertia, experts at ASN Kidney Week 2026 pointed to pharmacists as key to moving new kidney data into practice.
From insurance delays to injection concerns, pharmacists can help patients navigate the first month and avoid preventable treatment interruptions.
Joshua J. Neumiller, PharmD, CDCES, of the American Diabetes Association, discusses pharmacists’ role in diabetes and CKD care at ASN Kidney Week 2026.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Diabetes Awareness Month Opens Amid New T1D, T2D Approvals
2
FDA Grants Accelerated Approval to First Plasmid DNA-Based Immunotherapy for Recurrent Respiratory Papillomatosis
3
Community Pharmacists Guide Patients New to Glucose Monitoring
4
Very Low Protein Intake Tied to Higher Kidney Failure Risk in CKD
5